Cargando…

Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)

AIMS: Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point‐of‐care tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot ulcers: venous white cell count, C‐reactive protein (CRP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ingram, J. R., Cawley, S., Coulman, E., Gregory, C., Thomas‐Jones, E., Pickles, T., Cannings‐John, R., Francis, N. A., Harding, K., Hood, K., Piguet, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811820/
https://www.ncbi.nlm.nih.gov/pubmed/28734103
http://dx.doi.org/10.1111/dme.13431
_version_ 1783299926264905728
author Ingram, J. R.
Cawley, S.
Coulman, E.
Gregory, C.
Thomas‐Jones, E.
Pickles, T.
Cannings‐John, R.
Francis, N. A.
Harding, K.
Hood, K.
Piguet, V.
author_facet Ingram, J. R.
Cawley, S.
Coulman, E.
Gregory, C.
Thomas‐Jones, E.
Pickles, T.
Cannings‐John, R.
Francis, N. A.
Harding, K.
Hood, K.
Piguet, V.
author_sort Ingram, J. R.
collection PubMed
description AIMS: Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point‐of‐care tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot ulcers: venous white cell count, C‐reactive protein (CRP) and procalcitonin, and a novel wound exudate calprotectin assay. Calprotectin is a marker of neutrophilic inflammation. METHODS: In a prospective study, people with uninfected or mildly infected diabetic foot ulcers who had not received oral antibiotics in the preceding 2 weeks were recruited from community podiatry clinics for measurement of inflammatory biomarkers. Antibiotic prescribing decisions were based on clinicians’ baseline assessments and participants were reviewed 1 week later; ulcer infection was defined by clinicians’ overall impression from their two assessments. RESULTS: Some 363 potential participants were screened, of whom 67 were recruited, 29 with mildly infected diabetic foot ulcers and 38 with no infection. One participant withdrew early in each group. Ulcer area was 1.32 cm(2) [interquartile range (IQR) 0.32–3.61 cm(2)] in infected ulcers and 0.22 cm(2) (IQR 0.09–1.46 cm(2)) in uninfected ulcers. Baseline CRP for mild infection was 9.00 mg/ml and 6.00 mg/ml for uninfected ulcers; most procalcitonin levels were undetectable. Median calprotectin level in infected diabetic foot ulcers was 1437 ng/ml and 879 ng/ml in uninfected diabetic foot ulcers. Area under the receiver operating characteristic curve for a composite algorithm incorporating calprotectin, CRP, white cell count and ulcer area was 0.68 (95% confidence intervals 0.52–0.82), sensitivity 0.64, specificity 0.81. CONCLUSIONS: A composite algorithm including CRP, calprotectin, white cell count and ulcer area may help to distinguish uninfected from mildly infected diabetic foot ulcers. Venous procalcitonin is unhelpful for mild diabetic foot ulcer infection.
format Online
Article
Text
id pubmed-5811820
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58118202018-02-16 Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study) Ingram, J. R. Cawley, S. Coulman, E. Gregory, C. Thomas‐Jones, E. Pickles, T. Cannings‐John, R. Francis, N. A. Harding, K. Hood, K. Piguet, V. Diabet Med Research Articles AIMS: Deciding if a diabetic foot ulcer is infected in a community setting is challenging without validated point‐of‐care tests. Four inflammatory biomarkers were investigated to develop a composite algorithm for mildly infected diabetic foot ulcers: venous white cell count, C‐reactive protein (CRP) and procalcitonin, and a novel wound exudate calprotectin assay. Calprotectin is a marker of neutrophilic inflammation. METHODS: In a prospective study, people with uninfected or mildly infected diabetic foot ulcers who had not received oral antibiotics in the preceding 2 weeks were recruited from community podiatry clinics for measurement of inflammatory biomarkers. Antibiotic prescribing decisions were based on clinicians’ baseline assessments and participants were reviewed 1 week later; ulcer infection was defined by clinicians’ overall impression from their two assessments. RESULTS: Some 363 potential participants were screened, of whom 67 were recruited, 29 with mildly infected diabetic foot ulcers and 38 with no infection. One participant withdrew early in each group. Ulcer area was 1.32 cm(2) [interquartile range (IQR) 0.32–3.61 cm(2)] in infected ulcers and 0.22 cm(2) (IQR 0.09–1.46 cm(2)) in uninfected ulcers. Baseline CRP for mild infection was 9.00 mg/ml and 6.00 mg/ml for uninfected ulcers; most procalcitonin levels were undetectable. Median calprotectin level in infected diabetic foot ulcers was 1437 ng/ml and 879 ng/ml in uninfected diabetic foot ulcers. Area under the receiver operating characteristic curve for a composite algorithm incorporating calprotectin, CRP, white cell count and ulcer area was 0.68 (95% confidence intervals 0.52–0.82), sensitivity 0.64, specificity 0.81. CONCLUSIONS: A composite algorithm including CRP, calprotectin, white cell count and ulcer area may help to distinguish uninfected from mildly infected diabetic foot ulcers. Venous procalcitonin is unhelpful for mild diabetic foot ulcer infection. John Wiley and Sons Inc. 2017-08-15 2018-02 /pmc/articles/PMC5811820/ /pubmed/28734103 http://dx.doi.org/10.1111/dme.13431 Text en © 2017 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Ingram, J. R.
Cawley, S.
Coulman, E.
Gregory, C.
Thomas‐Jones, E.
Pickles, T.
Cannings‐John, R.
Francis, N. A.
Harding, K.
Hood, K.
Piguet, V.
Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
title Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
title_full Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
title_fullStr Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
title_full_unstemmed Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
title_short Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study)
title_sort levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (induce study)
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811820/
https://www.ncbi.nlm.nih.gov/pubmed/28734103
http://dx.doi.org/10.1111/dme.13431
work_keys_str_mv AT ingramjr levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT cawleys levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT coulmane levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT gregoryc levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT thomasjonese levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT picklest levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT canningsjohnr levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT francisna levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT hardingk levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT hoodk levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy
AT piguetv levelsofwoundcalprotectinandotherinflammatorybiomarkersaidindecidingwhichpatientswithadiabeticfootulcerneedantibiotictherapyinducestudy